In vitro cytotoxicity of S16020-2, a new olivacine derivative

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 169-180

  Léonce, Stéphane ^a   Perez, Valérie ^a   Casabianca Pignede, Marie Rose ^a   Anstett, Monique ^a   Bisagni, Emile ^b   Pierre, Alain ^a   Atassi, Ghanem ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b CNRS   (France)

Author keywords

Adriamycin; Flow cytometry; Multidrug resistance; P glycoprotein; S16020 2; Topoisomerases

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTINIUM ACETATE; GLYCOPROTEIN P; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; OLIVACINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA B16; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; ETHIDIUM; HUMANS; ISOENZYMES; LEUKEMIA L1210; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0029844553     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jasztold-Howorko R, Landras C, Pierre A, Atassi G, Guilbaud N, Kraus-Berthier L, Leonce S, Rolland Y, Prost JF, Bisagni E: Synthesis and evaluation of 9-hydroxy-5-methyl-(5,6-dimethyl)-6H-pyrido[4,3b] carbazole-1-N([dialkylamino)alkyl] carboxamides, a new promising series of antitumor olivacine derivatives. J Med Chem 37:2445-2452, 1994
2. Kraus-Berthier L, Guilbaud N, Leonce S, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierre A, Atassi G: Antitumor effect of S16020-2 against experimental lung carcinoma. Proc Am Assoc Cancer Res 36:386, 1995
3. Le Mee S, Markovits J, Pierre A, Atassi G, Bisagni E, Jacquemin-Sablon A, Saucier JM: In vitro studies of S16020-2, a new antitumour pyridocarbazole derivative. The fifth conference on DNA topoisomerases in therapy. New York, 1994
4. Leonce S, Pierre A, Anstett M, Perez V, Genton A, Bizzari JP, Atassi G: Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol 44:1707-1715, 1992
5. Charcosset JY, Saucier JM, Jacquemin-Sablon A: Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. Biochem Pharmacol 37:2145-2149, 1988
6. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT: Altered catalytic activity of and DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869, 1988
7. Rouësse J, Spielmann M, Turpin F, Le Chevalier T, Azab M, Mondesir JM: Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer 29A:856-859, 1993
8. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601, 1988
9. Pierre A, Kraus-Berthier L, Atassi G, Gros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP: Preclinical antitumor activity of a new vinca alkaloid derivative, S12363. Cancer Res 51:2312-2318, 1991
10. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
11. Baisch H, Gerdes J: Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 20:387-391, 1987
12. Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi Ricotti GBC, Bottiroli G: Topoisomerase IIα and β in human tumor cells grown in vitro and in vivo. Anticancer Res 12:2093-2100, 1992
13. Negri C, Chiesa R, Cerino A, Bestano M, Sala C, Zini N, Maraldi M, Astraldi Ricotti GBC: Monoclonal antibodies to human-DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Rec 200:452-459, 1992
14. Le Pecq JB, Paoletti C: A fluorescent complex between ethidium bromide and nucleic acids. Physical-chemical characterization. J Mol Biol 27:87-106, 1967
15. Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P, Martin F: Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res 50:6626-6631, 1990
16. Dimanche-Boitrel MT, Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, Ardiet C, Bastian G, Chauffert B: Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 50:677-682, 1992
17. Bhuyan BK, McGovren JP, Crampton SL: Intracellular uptake of 7-con-O-methylnogarol and adriamycin by cells in culture and its relationship to cell survival. Cancer Res 41:882-887, 1981
18. Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48:3230-3235, 1988
19. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell growth Diff 2:209-214, 1991
20. Davies SM, Robson CN, Davies SL, Hickson ID: Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724-17729, 1988
21. Zunino F, Capranico G: DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-Cancer Drug Design 5:307-317, 1990
22. Fosse P, Rene B, Charta M, Paoletti C, Saucier JM: Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol 42:590-595, 1992
23. De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F: Evidence of DNA-topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukaemia cells. Mol Pharmacol 37:11-16, 1990
24. Leonce S, Anstett M, Perez V, Pierre A: Flow cytometric evaluation of the cell cycle perturbations induced by S12363, a new vinca-alkaloid derivative. Anti-cancer Drugs 1:179-183, 1990
25. Solary E, Leteurtre F, Paul KD, Scuderio D, Hamel E, Pommier Y: Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45:2449-2456, 1993
26. Yoshinari T, Yamada A, Uemoura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, Okura A: Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490-494, 1993